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INTRODUCTION 
Plasmacytomas are malignant neoplasms of plasma cells classified as mature B-cell neoplasms 
[1]. Plasma cell neoplasms include extramedullary plasmacytoma (EMP), solitary bone 
plasmacytoma (SBP), multiple myeloma (MM), and the syndromes defined by the consequence 
of tissue immunoglobin deposition i.e. amyloidosis and light and heavy chain deposition 
diseases. EMPs are localized plasma cell neoplasms that arise in tissues other than bone [1]. 
The lesion can be either a primary plasmacytoma of the mucosa, unifocal or multifocal, with or 
without affected lymph nodes or extramedullary manifestations of MM [2]. EMP accounts for 
only 3-5% of all plasma cell neoplasms and 1% of all head and neck tumours but 80% of them 
originate in the head and neck region. However, they comprise only 4% of all non-epithelial 
tumours of the sinonasal tract [1, 3, 4].  
 
Two thirds of EMP patients are male, and their median age is 55 years [1]. The disease is 
typically localized, and the incidence of lymph node involvement is 10-20% [5]. Fifteen to 20% 
of the cases progress to MM or regional disease [4]. MM is more common in SBP where the 
conversion rates vary between 48% and 85% [3, 4]. Radiotherapy is the treatment of choice but 
there is no consensus on the optimal radiation dose. Doses of > 45 Gy are considered to be safe 
but 35 Gy is found to be sufficient for small tumours [6]. In that study which included 14 
patients with EMP in different soft tissue area, patients were treated with 35 Gy, and the only 
failed case was in a patient with a large primary tumour > 5 cm. In the study by Tournier-
Rangeard et al. local control and disease-free survivals seemed to be dose dependent. The 5-
year local control rate was 100% for the patients who received > 45 Gy and 50% for the patients 
who received < 45 Gy [7].  
In their 2004 guidelines, the UK Myeloma Forum recommends doses of 40-50 Gy [8]. Surgery 
is used alone or with pre- or postoperative radiotherapy in small or localized cases. 
Chemotherapy has only been used only in some rare cases [9, 10]. According the U.K. Myeloma 
Forum, chemotherapy should be considered for EMP patients if the tumour is > 5 cm, for high-
grade tumours, for refractory and or relapsed disease and in therapy for MM [8].   
Larger EMP series have been reported but these typically include tumours from the oropharynx, 
larynx, parotid gland, orbit, and neck [5, 10-15]. Also, many studies include patients with EMP 
and SBP together [11, 16, 17]. To our knowledge the largest study so far includes 68 solitary 
EMPs with 37 cases in the sinonasal tract or nasopharynx [10]. The rarity and the long clinical 
course of this disease entity lead to difficulties in determining prognostic factors and in 
determining the optimal management. 
In the present study, we have retrospectively analysed an institutional series of patients with 
sinonasal tract or nasopharyngeal EMP in order to delineate their main clinical characteristics 
and optimal management. We also emphasize this entity as a rare differential diagnostic 
alternative when a sinonasal or nasopharyngeal mass is encountered in patients with persistent 
nasal complaints.  
 
PATIENTS AND METHODS 
A retrospective review was performed of all patients diagnosed and treated for an EMP of the 
sinonasal tract or nasopharynx at the Departments of Otorhinolaryngology - Head and Neck 
Surgery and Oncology, Helsinki University Hospital (HUH), Helsinki, Finland between 1975 
and 2013. The patients with a verified disease in the nasopharynx, nasal cavity or paranasal 
sinuses were identified from the files of the Department of Pathology, University of Helsinki. 
In addition, data for the same geographical area during this time period were collected from the 
nationwide Finnish Cancer Registry to ensure that all the patients diagnosed in the 
corresponding hospital referral area were included in the study (Malila N, personal 
communication, 2015). All plasmacytoma diagnoses were reviewed and confirmed by an 
experienced hematopathologist (M.-L.K.-L.). The study group consisted of 25 patients with 
adequate clinical and histopathological data available. Data on patient characteristics, and 
clinical and histological details were recorded. All patients had a minimum follow-up time of 
27 months or until death. SPSS Statistics (IBM Corp. Released 2013. IBM SPSS Statistics for 
Windows, Armonk, NY: IBM Corp.) was used for statistical analyses. Institutional research 
approval was granted for the study.  
 
RESULTS 
The median age at diagnosis was 66 years (range, 36-80) and eighteen patients (72%) were 
male. The duration of symptoms prior to diagnosis was available for 23 patients (median 5 
months; range, 0-24). Nasal symptoms were the most common (n=17, 68%). Thirteen patients 
(52%) had bloody discharge, and 11 (44%) had nasal blockage. Six patients (24%) had eye 
symptoms. Three of them had double images, and two had lost their vision. Many patients had 
several of these symptoms (Table 1). 
In nine patients (36%), the disease occurred in the nasopharynx including eight cases (32%) 
with nasopharynx as the single location. The nasal cavity was affected in 14 patients (56%) and 
it was in a single sinonasal location in 9 patients (36%). Paranasal sinuses were involved in 8 
cases (32%) with 3 cases (12%) with paranasal sinuses as the single site. Seven patients (28%) 
with paranasal involvement had bone erosion in their orbits or skull base.  
In 22 cases (88%) EMP was the primary plasma cell neoplasm. In total, four patients with 
primary EMP experienced progression to MM during the follow up and they all died from their 
disease. In two patients, systemic disease had been diagnosed with MM one year earlier, and 
they both died one to two months after EMP management with radiotherapy. One patient had 
two years earlier been diagnosed with non-Hodgkin lymphoma, and was then diagnosed first 
with EMP in the neck, and three years later in the tongue and nasopharynx. He was treated with 
radiotherapy but died 29 months later due to T cell lymphoma. 
Four patients (16%) were primarily treated only with surgery. Two of the operated patients 
(tumour in the nasopharynx or in the nasal concha) had a local recurrence after two to three 
years, and both were successfully treated with radiotherapy and they died from an unknown or 
other cause 111 and 195 months later, respectively. For one patient with a septal lesion, surgery 
and postoperative radiotherapy were recommended but the free margins in the surgical tumour 
specimen were considered sufficient and the radiotherapy was not done. The patient died of 
another cause 40 months later without a local relapse. The last patient with a septal tumour has 
been followed for 27 months with no evidence of the disease reoccurring. 
Altogether four of the patients received a combination of surgery and (chemo)radiotherapy. In 
two of these patients the first histology was ambiguous and after a wider surgical resection the 
margins were still non-radical. Despite postoperative radiotherapy or chemotherapy they both 
died either of MM or treatment-related cause, respectively. One patient received postoperative 
radiotherapy because of he was relatively young (41years) and he had an uneventful follow up 
for 89 months. In one patient, the tumour residual after radiotherapy was surgically removed 
from the nasal cavity and he had an uneventful follow up for 50 years. 
Seventeen patients (68%) were primarily treated with only radiotherapy or 
(chemo)radiotherapy. The mean dose was 44.7 Gy (median 50 Gy; range, 30-50). Eight patients 
(47%) had a complete response to primary radiotherapy and have been without local relapse or 
progression to MM with a median follow-up time of 89 months (range, 40-245). One patient 
had a complete response after receiving additional brachytherapy and has been uneventfully 
followed for 190 months. Five patients perished due to MM of these two patients had MM 
before EMP diagnosis and one had local spreading before MM. One patient developed an EMP 
recurrence eight months after radiotherapy and additionally a diffuse large B-cell lymphoma 19 
months after primary EMP and died from the lymphoma. The other patients died either of 
treatment-related sepsis (one patient) or T-cell lymphoma (one patient). 
Treatment, outcome, and follow-up data are shown in Table 2a-b. 
In the whole series, 11 patients (44%) were alive with no evidence of disease after a median 
follow-up time of 78 months (range, 27 - 245). Three of these 11 patients had bone erosion to 
the orbit and one also to the lamina cribriformis, but they were successfully treated with 
radiotherapy and followed for 77, 78, 245 months, respectively (Figure 1 and 2 for one patient). 
Ten patients (40%) died from MM or other lymphoid malignancy after a median follow-up time 
of 23 months (range, 1-56). Four patients had died from other diseases with a median follow-
up time of 105 months (range, 40-195).  
The median age at diagnosis was 65 years for the patients who were free of the disease or had 
died from other reasons during this follow up and 68.5 years for those patients who had died 
from EMP, MM or other lymphoid malignancy.  
In the statistical analyses significant differences were not observed in the patient characteristics 
between the group that was treated with radiotherapy and the group that was not treated with 
radiotherapy. In multivariate analyses age at diagnosis, location, sex or treatment did not have 




We present a single-institution review of 25 patients with sinonasal tract or nasopharyngeal 
EMPs over almost four decades. This is a large population-based analysis that includes 
practically all the patients diagnosed with sinonasal or nasopharyngeal EMP in this referral area 
of 1.6 million inhabitants covering almost one third of the Finnish population. To ensure that 
all the patients were included, we also received data from the nationwide Finnish Cancer 
Registry, which has been functioning for over six decades and has complete coverage of the 
cancer cases in Finland.  
The present study comprises one of the largest clinical series of patients with EMP only 
involving the sinonasal tract and nasopharynx. In a Canadian study of 68 solitary EMP cases in 
the head and neck area 37 EMP cases were diagnosed in the nasal cavity, paranasal sinuses or 
nasopharynx [10]. The sinonasal tract was the most common site. Fifty-seven percent were 
treated with radiotherapy, 12% with surgery, 21% with surgery and radiotherapy and four 
percent with chemoradiotherapy in their series. The 5-year local-recurrence-free survival was 
81%. There was a trend towards improved local recurrence-free rate in patients with primary 
radiotherapy. The 5-year regional-recurrence-rate was five percent. MM developed in 23% and 
the 5-year survival was 76% [10]. In another study of 67 EMP cases of the head and neck at 23 
Japanese institutions 43 EMP cases examined were in the sinonasal tract or pharynx. The 
overall 5- and 10-year survival rates were 73% and 56%, respectively and the cause-specific 5- 
and 10-year survival rates were 82% and 76%, respectively [15]. The disease progressed in 
36% of patients and 12% developed MM. Every patient received radiotherapy and in 28% of 
them surgery preceded radiotherapy. In eight percent radiotherapy was combined with 
chemotherapy and in six percent radiotherapy was followed by surgery with or without 
chemotherapy. Radiotherapy was quite effective but radiotherapy combined with surgery 
produced better survival rates [15].   
In a review of 67 studies including 175 EMP sinonasal patients, radiotherapy was the most 
common treatment modality. Radiotherapy alone was used in 89 cases (51%) followed by a 
combination of surgery and radiotherapy [18]. At the median follow-up of 39 months 72% of 
patients were alive, independent of treatment modality. Radiotherapy combined with 
chemotherapy was rarely used but had the best outcome with 89% (8/9) of the surviving patients 
(18). In this review, of the three most common treatments (radiotherapy alone, surgery alone, 
combination surgery and radiotherapy), radiotherapy alone was the most common treatment, 
but a combination of surgery and radiotherapy had the best outcome [18]. The majority of 
patients who developed MM had received radiotherapy alone as their primary management. 
The authors concluded that surgery should be considered for small tumours [18].  
The presenting symptoms in the present series started five months (median) prior to EMP 
diagnosis. Nasal blockage and bloody discharge were common symptoms but 24% had eye or 
neurological symptoms. Seven patients (28%) with paranasal involvement had bone erosion to 
their orbits or skull base. As the symptoms may be vague, they can be present for months or 
years prior to diagnosis [19]. 
Local recurrences as well as progression to MM in this cohort occurred within three years from 
the initial EMP diagnosis. In addition, one patient developed a diffuse large B-cell lymphoma 
within the same time period. Two years before the EMP, one patient had been diagnosed with 
Hodgkins lymphoma, and was then diagnosed first with EMP in the neck, and three years later 
in the tongue and nasopharynx and then further developed T-cell lymphoma. In our study, four 
primary EMP patients developed MM, three of which were primarily treated with radiotherapy 
and one with surgery followed by radiotherapy for local relapse. 
It is difficult to determine the optimal therapy for EMP because of the small number of patients 
in most studies. Further, as in most retrospective study settings, there is a selection bias for 
small tumours being treated with surgery. However, radiotherapy doses over 45 Gy are 
considered safe and effective [6, 7]. The mean dose 44.7 Gy (median 50 Gy; range, 30-50) used 
in our cohort is in accordance with this.  The role of systemic therapy is unclear except for the 
cases that progressed to MM. It has been suggested by the UK Myeloma Forum that 
chemotherapy should be considered in EMP treatments in cases with tumour diameters over 5 
cm, high-grade tumours, as well as refractory and/or relapsed disease, and for patients with 
simultaneous systemic MM [8].  
Our findings regarding male predominance (72%) and median age (66 years) are in accordance 
with the existing reports [10, 15, 18]. It has been previously reported that the overall survival 
is better for younger patients (< 60 years) and for patients with tumour diameter less than 4 cm 
(16). In our study the median age at diagnosis was 65 years for the patients who were free of the 
disease or had died of another cause during the follow up and 68.5 years for those patients who 
had died of EMP, MM or another lymphoid malignancy.  
According to previous reports the rate of conversion of EMP to MM is 15% to 20% (4). In a 
study of 17 EMP patients, 29% of them progressed to MM (14). In our study the conversion rate 
was 17% (4/23). Additionally, two patients have been followed for 27 to 44 months with MGUS 
without progression to MM. Additionally eight percent (2/25) were diagnosed with MM 
approximately one year prior to EMP. The conversion risk is at its highest during the first two 
years but it has been noted up to 15 years later [10]. When conversion to MM has occurred, less 
than 10% of patients will survive 10 years [2, 10]. There is some controversy whether EMP and 
MM are different phases of the same disease or two different clinical entities [10]. In our study, 
all six MM patients died of their disease.  
Radiotherapy combined with surgery was the only significant prognostic factor in the study by 
Sasaki et al. [15]. Tumour size, age, sex, radiotherapy dose and chemotherapy did not influence 
the prognosis [15]. In another study radiotherapy and serum β2 microglobulin <3.5 mg/L were 
favourable prognostic factors for local control, MM-free survival, and progression-free survival 
in patients with EMP [17]. In the present study no prognostic clinical factors were found by 
Cox analyses. Plasmacytomas treated with surgery combined with radiotherapy were localized, 
whereas tumours treated with radiotherapy had typically spread to adjacent structures and 
consequently, surgery was not considered for the primary treatment or it could have resulted in 
positive resection margins. Nonetheless, one patient had plasmacytoma in all his right paranasal 
sinuses and there was also bone destruction to the orbit and lamina cribriformis. This patient 
was treated only with radiotherapy and he was still disease free after 20 years. Two other 
patients had tumours in their maxillary sinus with bone destruction also in their orbits and they 
were also disease free after six years. The remaining four with paranasal involvement with bone 
erosion to their orbits or skull bases died. Two of them died from MM, one had already earlier 
diagnosed MM and on died from sepsis. This proves that even large tumours can be highly 
radiosensitive, and the local spreading of the disease does not alone predict its prognosis.  
Ghazizadeh et al. published a case report of a 24-year-old male with a large right maxillary 
tumour with bone destruction in the medial and lateral walls [20]. The tumour was radioresistant 
but responded to surgical treatment followed radiotherapy and was followed for one year 
without relapse [20]. One of our patients had surgical treatment for a remnant tumour after 
radiotherapy with complete response and has been followed for 50 months without local 
recurrence or developing MM.  
The present work has the limitations associated with retrospective studies. Symptoms, 
laboratory findings, histopathology, treatment and survival data were recorded from patient 
files and some data on certain parameters were not available for all the patients. Imaging 
techniques have developed significantly during the past decades and have increased the 
information on the distribution of the disease but they were not available for the first cases in 
this series.  
 
CONCLUSIONS 
EMP in the sinonasal tract and nasopharynx is a rare condition to be considered as a differential 
diagnosis for patients with a wide variety of continuous obstructive nasal symptoms. Radical 
treatment and long-term survival are achievable in this patient population. Our study supports 
radiotherapy as a treatment of choice, however for small tumours surgery alone or combined 
with radiotherapy may be considered. In this study, local recurrence as well as conversion to 
MM occurred within three years of primary EMP diagnosis. Local relapses were successfully 
salvaged, but all patients whose disease developed to MM or subsequent other lymphoid 
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